Skip to content
Screener

Cash & Equivalents at other companies

Eli Lilly logo
Eli LillyLLY
$8.95B+165%
Oruka Therapeutics, Inc. logo
Oruka Therapeutics, Inc.ORKA
$49.52M-40.7%
Shattuck Labs, Inc. logo
Shattuck Labs, Inc.STTK
$90.42M+48.5%
Alumis Inc. logo
Alumis Inc.ALMS
$63.89M-50.3%
Upstream Bio, Inc. logo
Upstream Bio, Inc.UPB
$96.72M+35.6%
Kymera Therapeutics logo
Kymera TherapeuticsKYMR
$124.48M-62.9%

Other financials

Income statement

See full
Operating income-$70.0M-47.5%
Net income-$69.7M-74.5%
EPS (diluted)-$0.98-55.6%

Balance sheet

See full
Total debt$100.8M+33.3%
Total equity$254.0M-37.7%
Total assets$400.4M-21.7%

Cash flow

See full
Operating cash flow-$66.3M-73.8%
CapEx--100%
Free cash flow-$66.3M-73.6%

Valuation

See full
Market cap$1.53B-54.2%
Enterprise value$1.34B-57.2%

Returns & leverage

See full
Return on equity-77.7%-221pp
Debt / equity0.4×+0.2×
Current ratio8.6×-12.5×

Where this comes from

Reported directly by MoonLake Immunotherapeutics in its filing.

Tagged under the XBRL concept us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents.

The source filing: MoonLake Immunotherapeutics’s 10-Q, filed May 11, 2026.

Filed
May 11, 2026, 8:55 AM EDT
Fiscal quarter
Q1 FY2026
Calendar quarter
Q1 2026
Accession
0001821586-26-000007
(in thousands)Three Months Ended March 31, 2026Three Months Ended March 31, 2025
Net cash flow provided by financing activities30,64473,122
Effect of movements in exchange rates on cash held(483)(88)
Net change in cash and cash equivalents(36,027)91,140
Cash and cash equivalents, beginning of period334,517180,426
Cash and cash equivalents, end of period$298,490$271,566
Supplementary disclosure of cash flow information:
Cash paid for interest$1,819
Non-cash operating lease right-of-use assets obtained in exchange for lease obligations$567

Item 1. Financial Statements (Unaudited)

FAQ

What is MoonLake Immunotherapeutics's cash & equivalents?
MoonLake Immunotherapeutics (MLTX) reported cash & equivalents of $298.49M in Q1 2026.
How has MoonLake Immunotherapeutics's cash & equivalents changed year-over-year?
MoonLake Immunotherapeutics's cash & equivalents increased by 9.9% year-over-year, from $271.6M to $298.49M.
What is the long-term trend for MoonLake Immunotherapeutics's cash & equivalents?
Over 5 years (2020 to 2025), MoonLake Immunotherapeutics's cash & equivalents has grown at a 203.5% compound annual growth rate (CAGR), from $1.3M to $334.52M.
What does cash & equivalents mean?
Cash on hand plus highly liquid investments with maturities of three months or less at purchase — treasury bills, money market funds, and commercial paper.

Ask your AI about MoonLake Immunotherapeutics's cash & equivalents.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude